181 related articles for article (PubMed ID: 32531717)
1. Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study.
Thompson AB; Quinn TJ; Siddiqui ZA; Almahariq MF; Grills IS; Stevens CW
Lung Cancer; 2020 Aug; 146():120-126. PubMed ID: 32531717
[TBL] [Abstract][Full Text] [Related]
2. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA
Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
Nelson DB; Rice DC; Niu J; Atay S; Vaporciyan AA; Antonoff M; Hofstetter WL; Walsh GL; Swisher SG; Roth JA; Tsao A; Gomez D; Giordano SH; Mehran R; Sepesi B
J Clin Oncol; 2017 Oct; 35(29):3354-3362. PubMed ID: 28817374
[TBL] [Abstract][Full Text] [Related]
4. Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions.
Larose F; Quigley N; Lacasse Y; Martel S; Lang-Lazdunski L
Lung Cancer; 2021 Jun; 156():151-156. PubMed ID: 33962765
[TBL] [Abstract][Full Text] [Related]
5. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.
Taioli E; Wolf AS; Camacho-Rivera M; Kaufman A; Lee DS; Nicastri D; Rosenzweig K; Flores RM
PLoS One; 2015; 10(12):e0145039. PubMed ID: 26660351
[TBL] [Abstract][Full Text] [Related]
6. Fast neutron radiotherapy in the treatment of malignant pleural mesothelioma.
Patel SA; Kusano AS; Truong A; Stelzer KJ; Laramore GE
Am J Clin Oncol; 2015 Feb; 38(1):47-50. PubMed ID: 25616202
[TBL] [Abstract][Full Text] [Related]
7. Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma.
Alnajar A; Kareff SA; Razi SS; Rao JS; De Lima Lopes G; Nguyen DM; Villamizar N; Rodriguez E
JAMA Netw Open; 2023 Mar; 6(3):e234261. PubMed ID: 36951862
[TBL] [Abstract][Full Text] [Related]
8. Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Grover S; Friedberg JS; Simone CB
J Thorac Cardiovasc Surg; 2019 Feb; 157(2):758-766.e1. PubMed ID: 30454981
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma.
Casiraghi M; Maisonneuve P; Brambilla D; Solli P; Galetta D; Petrella F; Piperno G; De Marinis F; Spaggiari L
Eur J Cardiothorac Surg; 2017 Nov; 52(5):975-981. PubMed ID: 28482086
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
Kim RY; Li Y; Marmarelis ME; Vachani A
Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
Marulli G; Faccioli E; Bellini A; Mammana M; Rea F
Expert Rev Respir Med; 2017 Aug; 11(8):649-660. PubMed ID: 28580813
[TBL] [Abstract][Full Text] [Related]
12. Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database.
Abdel-Rahman O
Strahlenther Onkol; 2017 Apr; 193(4):276-284. PubMed ID: 28044200
[TBL] [Abstract][Full Text] [Related]
13. Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
Espinoza-Mercado F; Borgella JD; Berz D; Alban RF; Sarkissian A; Imai HTA; Soukiasian HJ
Ann Thorac Surg; 2019 Sep; 108(3):889-896. PubMed ID: 31004585
[TBL] [Abstract][Full Text] [Related]
14. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.
Nelson DB; Rice DC; Niu J; Atay SM; Vaporciyan AA; Antonoff MB; Hofstetter WL; Walsh GL; Swisher SG; Roth JA; Tsao AS; Gomez DR; Giordano SH; Mehran RJ; Sepesi B
Eur J Cardiothorac Surg; 2018 May; 53(5):960-966. PubMed ID: 29211849
[TBL] [Abstract][Full Text] [Related]
15. Management of Malignant Pleural Mesothelioma in the Elderly Population.
Verma V; Wegner RE; Ludmir EB; Hasan S; Colonias A; Grover S; Friedberg JS; Simone CB
Ann Surg Oncol; 2019 Aug; 26(8):2357-2366. PubMed ID: 31011908
[TBL] [Abstract][Full Text] [Related]
16. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
Remon J; Nadal E; Dómine M; Ruffinelli J; García Y; Pardo JC; López R; Cilleruelo A; García-Campelo R; Martín P; Juan O; González-Larriba JL; Provencio M; Olmedo E; Ponce S; Cumplido D; Barenys C; Majem M; Massutti B; Rodriguez-Abreu D; Porta R; Sala MA; Martinez-Kareaga M; Lianes P; Reguart N
Lung Cancer; 2020 Sep; 147():83-90. PubMed ID: 32682189
[TBL] [Abstract][Full Text] [Related]
17. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
Hasani A; Alvarez JM; Wyatt JM; Bydder S; Millward M; Byrne M; Musk AW; Nowak AK
J Thorac Oncol; 2009 Aug; 4(8):1010-6. PubMed ID: 19546819
[TBL] [Abstract][Full Text] [Related]
18. Current trends in the management of malignant peritoneal mesothelioma.
Miura JT; Johnston FM; Gamblin TC; Turaga KK
Ann Surg Oncol; 2014 Nov; 21(12):3947-53. PubMed ID: 24841356
[TBL] [Abstract][Full Text] [Related]
19. Malignant pleural mesothelioma characteristics and outcomes: A SEER-Medicare analysis.
Taioli E; Wolf A; Alpert N; Rosenthal D; Flores R
J Surg Oncol; 2023 Jul; 128(1):134-141. PubMed ID: 36932968
[TBL] [Abstract][Full Text] [Related]
20. Trimodality management of malignant pleural mesothelioma.
Maggi G; Casadio C; Cianci R; Rena O; Ruffini E
Eur J Cardiothorac Surg; 2001 Mar; 19(3):346-50. PubMed ID: 11251277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
